

Appendix 1: Trials investigating bupropion (page 1 of 2)

Study	Sample size	Design	Country	Mean CPD	Smoking abstinence (%)							
					6 Months				12 Months			
					Point prevalence		Continuous		Point prevalence		Continuous	
					Active	Control	Active	Control	Active	Control	Active	Control
Tonnesen 2003 ¹	707	R, DB, PC, MC	8 countries	23	33	18	25	13	28	14	21	11
Jorenby 2006* ²	683	R, DB, PC, MC	USA	22	26	25	NR	NR	23	17	NR	NR
Gonzales 2006* ³	673	R, DB, PC, MC	USA	21	25	15	NR	NR	23	14	NR	NR
Ahluwalia 2002† ⁴	600	R, DB, PC	USA	17	21	14	12	6	NR	NR	NR	NR
Fossati 2007 ⁵	593	R, DB, PC, MC	Italy	23	38	24	NR	NR	35	20	25	14
Collins 2004‡ ⁶	555	R, DB, PC, MC	USA	21	26	16	NR	NR	NR	NR	NR	NR
Aubin 2004 ⁷	504	R, DB, PC, MC	France	NR	31	16	25	13	NR	NR	NR	NR
Gonzales 2001 ⁸	450	R, DB, PC, MC	USA	NR	21	10	12	2	NR	NR	NR	NR
Jorenby 1999* ⁹	404	R, DB, PC, MC	USA	27	35	19	NR	NR	30	16	18	6
Dalsgaro 2004 ¹⁰	336	R, DB, PC, MC	Denmark	19	23	11	18	7	NR	NR	NR	NR
Hurt 1997* ¹¹	309	R, DB, PC, MC	USA	27	27	16	NR	NR	23	12	NR	NR
Muramoto 2007 i*§ ¹²	208	R, DB, PC, MC	USA	NR	9	6	NR	NR	NR	NR	NR	NR
Muramoto 2007 ii*§ ¹²	207	R, DB, PC, MC	USA	NR	2	6	NR	NR	NR	NR	NR	NR
Hall 2002* ¹³	146	R, DB, PC	USA	22	25	16	NR	NR	25	14	21	12
Holt 2005*¶ ¹⁴	134	R, DB, PC	NZ	NR	NR	NR	30	11	NR	NR	22	11

Note: CPD = cigarettes per day, R = randomized, DB = double-blind, NZ=New Zealand, PC = placebo controlled, MC = multi-center, NR = not reported.

References appear on the next page.

*Number of subjects included in the analysis: participants who were not randomized to either 300 mg bupropion SR or placebo, or received more than one smoking cessation pharmacotherapy or medications other than those included in our study were excluded from our analyses.

†This study exclusively recruited African American smokers.

‡Results obtained in part through correspondence.

§Muramoto et al. randomized patients to 150 mg/day of bupropion (i), 300 mg/day of bupropion (ii), or placebo.

¶This study exclusively recruited smokers previously treated with bupropion SR and indigenous Maori of New Zealand.

References to Appendix 1 (page 2 of 2)

1. Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. *J Intern Med* 2003;254:184-92.
2. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:56-63.
3. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:47-55.
4. Ahluwalia JS, Harris KJ, Catley D, et al. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. *JAMA* 2002;288:468-74.
5. Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. *Arch Intern Med* 2007;167:1791-7.
6. Collins BN, Wileyto EP, Patterson F, et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. *Nicotine Tob Res* 2004;6:27-37.
7. Aubin HJ, Lebagry F, Berlin I, et al. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. *Addiction* 2004;99:1206-18.
8. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. *Clin Pharmacol Ther* 2001;69:438-44.
9. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med* 1999;340:685-91.
10. Dalsgareth OJ, Hansen NC, Soes-Petersen U, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. *Nicotine Tob Res* 2004;6:55-61.
11. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med* 1997;337:1195-202.
12. Muramoto ML, Leischow SJ, Sherrill D, et al. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. *Arch Pediatr Adolesc Med* 2007;161:1068-74.
13. Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. *Arch Gen Psychiatry* 2002;59:930-6.
14. Holt S, Timu-Parata C, Ryder-Lewis S, et al. Efficacy of bupropion in the indigenous Maori population in New Zealand. *Thorax* 2005;60:120-3.